Predictors of relapse in graves' hyperthyroidism after treatment with antithyroid drugs

Background: Choice of the treatment for patients with Graves' hyperthyroidism depends on local preference, the higher recurrence risk, comorbidities, and the patient's preferences. About half of the patients relapse after a course of a standard antithyroid drug (ATD) therapy for Graves' disease. Objectives: The objective of this study was to determine the clinical and biochemical features of Graves' hyperthyroidism that can predict the relapse of the disease after a standard course of ATD therapy. Patients and Methods: We conducted a retrospective 6-month study of 79 patients with Graves' hyperthyroidism who were treated with ATD (carbimazole) therapy for 12–18 months and went into remission for at least 1 year after ATD withdrawal. Results: The relapse rate in Graves' hyperthyroidism after 1 year in remission was 40.5%; patients with younger age (<40 years) and with severe biochemical disease correlated significantly with relapse. Gender, presence of a palpable goiter, orbitopathy, and smoking habits were not significant predictors of relapse, perhaps because of the small sample size. Conclusions: Forty percent of Graves' hyperthyroidism relapsed after 1 year of remission. Younger age and severe biochemical disease at diagnosis predicted relapse.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Predictors of relapse in graves' hyperthyroidism after treatment with antithyroid drugs ; volume:10 ; number:06 ; year:2018 ; pages:205-208 ; Ibnosina journal of medicine and biomedical sciences ; 10, Heft 06 (2018), 205-208

Contributors, Places and Time

• Contributor: Lawgaly, Sami ; Kallousa, Houda ; Gerryo, Salaheldin

Further information

• DOI: 10.4103/ijmbs.ijmbs_75_18
• URN: urn:nbn:de:101:1-2022101004123039549126
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:35 AM CEST